FIIN-1 NEW
| Price | $72 | $105 | $213 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: FIIN-1 | CAS No.: 1256152-35-8 |
| Purity: 98.75% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | FIIN-1 |
| Description | FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt14, respectively.FIIN-1 inhibited FGFR1, FGFR2, FGFR3, FGFR4, with IC50 of 9.2, 6.2, 11.9 and 189 nM. FIIN-1 inhibited FGFR1, FGFR2, FGFR3 and FGFR4, with IC50s of 9.2, 6.2, 11.9 and 189 nM, respectively. |
| In vitro | FIIN-1 (14 nM-46 μM; 72 h; ) inhibits the proliferation of FGF signaling-sensitive cancer cell lines. The EC50s of 70 nM, 230 nM, 2.3 μM, for Bladder RT4, Pancreas A2.1, Bone RD-ES cells. EC50s of 0.22 and 4.6 μM for Ovary A2780 and PA-1 cells, respectively. EC50s of 0.08 and 4.5 μM for Lung SBC-3 and H520 cells, respectively. EC50s of 0.14 and 1.65 μM for Kidney G-401 and G-402 cells, respectively. EC50s of 0.014, 0.03, and 0.65 μM for Stomach KATO III, SNU-16, and FU97 cells, respectively.[1] FIIN-1 (20 nM) inhibits iFGFR1 autophosphorylation and its downstream Erk1/2 almost completely.[1] FIIN-1 binds to BLK, ERK5, KIT, MET, PDGFRB, and VEGFR2 with Kds of 65 nM, 160, 420, 1000, 480, and 210 nM, respectively. The IC50s for Blk and Flt1 are 381 nM and 661 nM respectively.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.05 mM), Sonication is recommended. DMSO : 45 mg/mL (68.53 mM), Sonication is recommended. |
| Keywords | FIIN-1 | FIIN1 | FIIN 1 | FGFR |
| Inhibitors Related | Amlexanox | Regorafenib monohydrate | Nintedanib | Ferulic Acid | Nintedanib esylate | Regorafenib | Pemigatinib | Formononetin | Lenvatinib mesylate | Erdafitinib | Lenvatinib | Pazopanib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Osteogenesis Compound Library | Cysteine Covalent Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | ||
| $999.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-26 | |
|
VIP8Y
|
ROSEWA HOLDING GROUP CO.,LIMITED
|
2026-06-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY